I don’t play in the DEA space, but believe it is Elite showing the demand to DEA and getting allotment. Would love to hear from someone who is actually close to this.
Prasco has history as AG, but is simply switching to Elite as Mfr. I would think that historic volume of sales would be leverage to get quota aligned with historic levels from old mfr.
Curious what impact to margin or profit share will be as AG should be little higher in price. I’m curious how different the recipe & process is for AG vs their standard generic XR product. I don’t think it’s the exact same. Generic has same active ingredients as brand, but I think AG has to have everything be exact as brand so I’d expect a different cost profile too.
News 
Market Data 
Discover 
